medigraphic.com
ISSN 1561-2988 (Print)

2014, Number 3

<< Back Next >>

Rev Cubana Farm 2014; 48 (3)

Effects of policosanol on gastroprotective action of D-002

Carbajal QD, Molina CV, Ravelo CY, Zamora RZ, Mas FR

Language: English
References: 40
Page: 486-494
PDF size: 88.13 Kb.


ABSTRACT

Introduction: policosanol, a mixture of higher aliphatic alcohols purified from sugar cane wax, is used to treat hypercholesterolemia. D-002 (Abexol), a mixture of higher aliphatic alcohols from beeswax, is an antioxidant supplement with gastroprotective effects. Then, concomitant intake of D-002 and policosanol may occur in routine practice, so potential pharmacological interactions between them should be researched on.
Objective: to find out the influence of policosanol on the gastroprotective effect of D-002 on the ethanol-induced gastric ulcer model.
Methods: rats were randomized into eight groups: one treated with the vehicle (control), two with D-002 (25 and 200 mg/kg), two with policosanol (25 and 200 mg/kg), two with the same doses of D-002 + policosanol and other with sucralfate (100 mg/kg). Treatments were given as single oral doses. One hour after treatment, rats received 60% ethanol orally and one hour later they were killed and their stomachs exposed. Effects on ulcer indexes (UI) were assessed.
Results: acute oral administration of D-002 (25 and 200 mg/kg) significantly reduced the ulcer indexes by 40 % and 68 %, respectively, as compared to the control group, and policosanol by 26 % and 47 %, respectively. The concomitant administration of the same doses of D-002 and policosanol significantly decreased ulcer indexes by 64 % (both given at 25 mg/kg) and by 92 % (both given at 200 mg/kg) as compared to the respective monotherapies. Sucralfate (100 mg/kg) significantly reduced ( 99 %) ulcer indexes compared to the control group.
Conclusions: the concomitant oral administration of policosanol with D-00 2 gives greater gastroprotection than D-002 monotherapy, so both products can be taken together.


REFERENCES

  1. Zapata-Colindres JC, Zepeda-Gómez S, Montaño-Loza A, Vázquez-Ballesteros E, Villalobos JJ, Valdovinos-Andraca F. The association of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease. Can J Gastroenterol. 2006;20:277-80.

  2. Sung JY, Tosí KF, Ma TK, Yung MY, Lau YW, Chiu WY. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10 428 cases. Am J Gastroenterol. 2010;105:84-9.

  3. Zullo A, Hassan C, Campo SM, Morini S. Bleeding peptic ulcer in the elderly: risk factors and prevention strategies. Drugs Aging. 2007;24:815-28.

  4. Shiotani A, Manabe N, Kamada T, Fujimura Y, Sakakibara T, Haruma K. Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review. Gastroenterol Hepatol. 2012;27(Suppl 3):8-12.

  5. Iwamoto J, Saito Y, Honda A, Matsuzaki Y. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. World J Gastroenterol. 2013;19:1673-82.

  6. Ministerio de Salud Pública, Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud. La Habana: MINSAP; 2012.

  7. Allen A, Flemström G. Gastroduodenal mucus bicarbonate barrier: Protection against acid and pepsin. Am J Physiol Cell Physiol. 2005;288:C1-C19.

  8. Phillipson M, Johansson ME, Henriksnäs J, Petersson J, Gendler SJ, Sandler S, et al. The gastric mucus layers: constituents and regulation of accumulation. Am J Physiol Gastrointest Liver Physiol. 2008;295:G806-12.

  9. Palileo C, Kaunitz JD. Gastrointestinal defense mechanisms. Curr Opin Gastroenterol. 2011;27:543-8.

  10. Lamarque D. Pathogenesis of gastroduodenal lesions induced by non-steroidal anti-inflammatory drugs. Gastroenterol Clin Biol. 2004;28:C18-26.

  11. Yoshikawa T, Naito Y. Pathogenesis of NSAIDs-induced gastrointestinal ulcers. Nihon Rinsho. 2011;69:995-1002.

  12. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol. 2012;18:2147-60.

  13. Muresan A, Suciu S, Mitrea DR, Alb C, Login C, Crisan D, Daicoviciu D. Oxidative stress implications in experimental gastric ulcer induced by indomethacin. Bulletin UASVM, Veterinary Medicine. 2008;65(1):119-25.

  14. Parikh N, Howden CW. The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am. 2010;39:529-42.

  15. Fujikawa Y, Watanabe T, Tominaga K, Fujiwara Y, Sato H, Arakawa T. Efficacy of prostaglandin derivatives and mucoprotective drugs in treatment and prevention for NSAIDs-induced ulcer. Nihon Rinsho. 2011;69:1039-43.

  16. Heidelbaugh JJ, Metz DC, Yang YX. Proton pump inhibitors: are they over utilised in clinical practice and do they pose significant risk? Int J Clin Pract. 2012;66:582-91.

  17. Desilets AR, Asal NJ, Dunican KC. Considerations for the use of proton-pump inhibitors in older adults. Consult Pharm. 2012;27:114-10.

  18. Roulet L, Vernaz N, Giostra E, Gasche Y, Desmeules J. Adverse effects of proton pump inhibitors: Should we worry about long-term exposure? Rev Med Interne. 2012;33(8):439-45.

  19. Mas R. D-002: A product obtained from beeswax. Drugs of the Future. 2001;26(8):731-44.

  20. Carbajal D, Molina V, Valdés S, Arruzazabala ML, Más R. Anti-ulcer activity of higher primary alcohols of beeswax. J Pharm Pharmacol. 1995;47:731-3.

  21. Carbajal D, Molina V, Valdés S, Arruzazabala ML, Rodeiro I, Más R, et al. Possible cytoprotective mechanism in rats of D-002 an anti-ulcerogenic product isolated from beeswax. J Pharm Pharmacol. 1996;(48):858-60.

  22. Carbajal D, Molina V, Noa M, Valdes S, Arruzazabala ML, Aguiar A, et al. Effects of D-002 on gastric mucus composition in ethanol-induced ulcer. Pharmacol Res. 2000;42(4):329-32.

  23. Molina V, Valdés S, Carbajal D, Arruzazabala ML, Menéndez R, Mas R. Antioxidant effects of D-002 on gastric mucosa of rats with experimentally-induced injury. J Med Food. 2001;4:79-83.

  24. Pérez Y, Oyárzabal A, Mas R, Molina V, Jiménez S. Protective effect of D-002, a mixture of beeswax alcohols, against indomethacin-induced gastric ulcers and mechanism of action. Int J Nat Med. 2013;67(1):182-9.

  25. Hano O, Illnait J, Mas R, Fernández L, Piñol F, Fernández J. Effects of D-002, a Product Isolated from Beeswax, on Duodenal Ulcer: A Double-Blind, Placebo- Controlled Study. Curr Ther Res. 2001;62:394-407.

  26. Illnait J, Terry H, Mas R, Fernandez L, Carbajal D. Effects of D-002, a product isolated from beeswax, on gastric symptoms of patients with osteoarthritis treated with piroxicam: a pilot study. J Med Food. 2005;8(1):63-8.

  27. Illnait J, Rodríguez I, Molina V, Mendoza S, Mas R, Fernández L, et al. Effects of D-002 (beeswax alcohols) on gastrointestinal symptoms and oxidative markers in middle-aged and older subjects. Lat Am J Pharm. 2013;32:166-74.

  28. Castaño G, Fernández L, Illnait J, Fernández J, Mas R, Mesa M, et al. Effects of policosanol on patients with borderline to mildly increased serum cholesterol levels: A prospective, double-blind placebo-controlled study. Curr Ther Res Clin & Exp. 2003;142(7):277-84.

  29. Menéndez R, Más R, Amor AM, González RM, Fernández JC, Rodeiro I, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol. 2000;50:255-62.

  30. Menéndez R, Más R, Amor A, Fernández JC, González RM. Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-medíated lipid peroxidation. Curr Ther Res. 2000;61:609-20.

  31. Noa M, Mas R. Effect of policosanol on atherosclerotic plaque composition on aortas of Macaca arctoides monkeys. Arch Med Res. 2005;36:441-7.

  32. González V, Marrero D, Sierra R, Velázquez C, Vicente R. Nuevo método por cromatografía gaseosa capilar para el análisis del ingrediente activo D-002. Rev CENIC Ciencias Químicas. 2008;9:123-5.

  33. Marrero D, González V, Sierra R, Velázquez C. Validación de un nuevo método analítico por CG con columna capilar para la determinación de alcoholes alifáticos de alto peso molecular en el policosanol ingrediente activo. Rev Colombiana de Ciencias Quim Farm. 2008;37(1):62-8.

  34. Zengil H, Onuk E, Ercan ZS, Turker RK. Protective effect of Iloprost and UK 38 485 against gastric mucosal damage induced by various stimuli. Prostagl Leukotr Med. 1987;30:61-7.

  35. Ohara A, Sugiyama S, Hoshino H, Hamajima E, Goto H, Tsukamoto Y. Reduction of adverse effects of indomethacin by anti-allergic drugs in rat stomachs. Arzneim-Forsch Drug Res. 1992;42:1115-8.

  36. Muhammed Ashraf VK, Thamotharan G, Sengottuvelu S, Haja Sherief S, Sivakumar T. Evaluation of anti ulcer activity of Ficus pumila L. Leaf extract in albino rats. GJRMI. 2012;1(8):340-51.

  37. Pérez Y, Oyarzábal A, Ravelo Y, Mas R, Jiménez S, Molina V. Inhibition of COX and 5-LOX enzymes by D-002 (beeswax alcohols). Curr Top Nutr Res (Forthcoming). 2012.

  38. Pérez Y, Oyarzábal A, Jiménez S, Molina V, Mas R. Efecto secuestrador del D- 002 sobre radicales hidroxilo en mucosa gástrica. Rev Cubana Farm. 2012;46(1):87-96.

  39. Arruzazabala ML, Carbajal D, Molina V, Valdés S, Más R, García M. Estudio farmacológico de la interacción entre el policosanol y la aspirina en animales de experimentación. Rev Iberoam Tromb Hemost. 1992;5:17-20.

  40. Oyarzábal A, Molina V, Jiménez S, Curveco D, Mas R. Efectos del policosanol, el extracto de semillas de uva y su terapia combinada sobre marcadores oxidativos en ratas. Rev Cubana Farm. 2010;45(1):87-96.




2020     |     www.medigraphic.com